León-Lara X, Otero-Mendoza F

Idioma: Español
Referencias bibliográficas: 17
Paginas: 23-26
Archivo PDF: 291.83 Kb.

RESUMEN

El desarrollo de vacunas efectivas contra el nuevo coronavirus SARS-CoV-2 se considera una prioridad mayor de salud pública global, para poder controlar la trasmisión y propagación de la enfermedad. Se han planteado diferentes enfoques para diseñar y desarrollar vacunas contra COVID-19, entre las que se incluyen las que contienen péptidos basados en epítopos, las de proteínas recombinantes, de vectores virales, basadas en ácidos nucleicos y las inactivadas. Sin embargo, hasta mayo 2020, no se dispone de una vacuna aprobada contra COVID-19.

REFERENCIAS (EN ESTE ARTÍCULO)

1. WHO. Coronavirus disease 2019 (COVID-19). Situation Report-121. 2020. https://www.who.int/docs/defaultsource/ coronaviruse/situation-reports/20200520-covid- 19-sitrep-121.pdf?sfvrsn=c4be2ec6_2.

2. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506. doi:10.1016/S0140-6736(20)30183-5.

3. Lu R, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395 (10224): 565-74. doi:10.1016/S0140-6736(20)30251-8

4. WHO. WHO Coronavirus Disease (COVID-19) Dashboard. 2020. https://covid19.who.int/?gclid=Cj0KCQjwzZj2BR DVARIsABs3l9KLJJpn5E7ebnSwU0nWws-G2lGOeRTZA- 0VSz67zcdgJr61WSs1NfYAaAvzjEALw_wcB.

5. Corey BL, et al. A strategic approach to COVID-19 vaccine R&D. Science. 2020; 368 (6494): 948-50. doi:10.1126/ science.abc5312

6. WHO. DRAFT landscape of COVID-19 candidate vaccines. 22 May.2020 https://www.who.int/who-documentsdetail/ draft-landscape-of-covid-19-candidate-vaccines.

7. Walls AC, et al. Structure, function, and antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181 (2): 281-92. e6. doi:10.1016/j.cell.2020.02.058

8. Ju B, et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bio Rxiv. 2020. doi:10.1101/2020.03.21.990770

9. Bhattacharya M, et al. Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARSCOV- 2): Immunoinformatics approach. J Med Virol. 2020; 10.1002/jmv.25736. doi:10.1002/jmv.25736

10. Peele KA, et al. Design of multi-epitope vaccine candidate against SARS-CoV-2: In-Silico study. J Biomol Struct Dyn. 2020; 1-10. doi:10.1080/07391102.2020.1770127

11. Nascimento IP, Leite LCC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res. 2012; 45 (12): 1102-111. doi:10.1590/S0100- 879X2012007500142

12. Hansson M, et al. Design and production of recombinant subunit vaccines. Biotechnol Appl Biochem. 2000; 32 (2): 95-107. doi:10.1042/ba20000034

13. Lundstrom K. RNA viruses as tools in gene therapy and vaccine development. Genes (Basel). 2019; 10 (3): 189. doi:10.3390/genes10030189

14. Rollier CS, et al. Viral vectors as vaccine platforms: Deployment in sight. Curr Opin Immunol. 2011 (3): 377-82. doi:10.1016/j.coi.2011.03.006

15. Lihua H, Fengcai Z. A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector). ChiCTR2000031781. www.chictr.org.cn/showprojen. aspx?proj=52006%0D. Published 2020.

16. Zhu FC, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; S0140-6736(20)31208-3. doi:10.1016/S0140-6736(20)31208-3

17. Oxford University. Oxford COVID-19 vaccine begins human trial stage. 2020; 23 April. 2020. http://www.ox.ac. uk/news/2020-04-23-oxford-covid-19-vaccine-beginshuman- trial-stage.